A Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011
The main purpose of this study is to evaluate the efficacy and safety in subjects with advanced breast cancer treated with SYHX2011
Advanced Breast Cancer
DRUG: SYHX2011
Objective Response Rate (ORR) by Investigator, *Time Frame: Up to approximately 2 years
Progression-Free-Survival (PFS), Up to approximately 2 years|Time to progression (TTP), Up to approximately 2 years|Incidence of adverse events, Up to approximately 2 years
The main purpose of this study is to evaluate the efficacy and safety in subjects with advanced breast cancer treated with SYHX2011